NCT05458102View on ClinicalTrials.gov

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
DRUG

Vesatolimod

Administered orally

DRUG

Cobicistat

Administered orally

DRUG

Voriconazole

Administered orally

DRUG

Rifabutin

Administered orally

Trial Locations (5)

33014

Clinical Pharmacology of Miami, LLC., Miami

33147

Advanced Pharma, CR, LLC., Miami

33407

Triple O Research Institute, P.A., West Palm Beach

90806

Collaborative Neuroscience Research, LLC., Long Beach

08054

Hassman Research Institute, Marlton

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY